MSLN and Miyoshi myopathy: Firstly, MSLN has been shown to be a specific and safe target in MM; and secondly, the ongoing research on CAR design and efficacy enhancement of anti- MSLN CAR T cells as well as their combination with CI and oncolytic viruses has increased tumor infiltration, efficacy and persistence.